絞り込み

16639

広告

Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.

著者 Hemmingsen B , Sonne DP , Metzendorf MI , Richter B
Cochrane Database Syst Rev.2017 May 10 ; 5():CD012204.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (354view , 0users)

Full Text Sources

Medical

Miscellaneous

The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide. Whether dipeptidyl-peptidase (DPP)-4 inhibitors or glucagon-like peptide (GLP)-1 analogues are able to prevent or delay T2DM and its associated complications in people at risk for the development of T2DM is unknown.
PMID: 28489279 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード